1. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia
increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study.
Circulation 2000;101:1506–11.
2. Colditz GA, Manson JE, Stampfer MJ, et al. Diet and risk of clinical
diabetes in women. Am J Clin Nutr 1992;55:1018–23.
3. Feskens EJ, Bowles CH, Kromhout D. Carbohydrate intake and body mass
index in relation to the risk of glucose intolerance in an elderly population. Am J Clin
Nutr 1991;54:136–40.
4. Wright DW, Hansen RI, Mondon CE, Reaven GM. Sucrose-induced insulin
resistance in the rat: modulation by exercise and diet. Am J Clin Nutr
1983;38:879–83.
5. Reiser S, Hallfrisch J, Fields M, et al. Effects of sugars on indices
of glucose tolerance in humans. Am J Clin Nutr 1986;43:151–9.
6. Wolever TMS, Brand Miller J. Sugars and blood glucose control. Am
J Clin Nutr 1995;62:212S–7S [review].
7. Wolever TMS, Brand Miller J. Sugars and blood glucose control. Am
J Clin Nutr 1995;62:212S–7S [review].
8. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic
load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA
1997;277:472–7.
9. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load,
and risk of NIDDM in men. Diabetes Care 1997;20:545–50.
10. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors
determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and
Dutch cohorts of the Seven Countries Study. Diabetes Care 1995;18:1104–12.
11. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic
load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA
1997;277:472–7.
12. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load,
and risk of NIDDM in men. Diabetes Care 1997;20:545–50.
13. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding
sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus.
Am J Clin Nutr 1989;50:474–8.
14. Abraira C, Derler J. Large variations of sucrose in constant
carbohydrate diets in type II diabetes. Am J Med 1988;84:193–200.
15. Loghmani E, Rickard K, Washburne L, et al. Glycemic response to
sucrose-containing mixed meals in diets of children with insulin-dependent diabetes mellitus.
J Pediatr 1991;119:531–7.
16. American Diabetes Association. Position Statement: nutrition
recommendations and principles for people with diabetes mellitus. Diabetes Care
1999;22:S42–5 [review].
17. Brand-Miller J, Foster-Powell K. Diets with a low glycemic index:
from theory to practice. Nutr Today 1999;34:64–72 [review].
18. Chandalia M, Garg A, Lutjohann D, et al. Beneficial effects of high
dietary fiber intake in patients with type 2 diabetes mellitus. New Engl J Med
2000;342:1392–8.
19. Rodríguez-Morán M, Guerrero-Romero F, Lazcano-Burciaga G.
Lipid- and glucose-lowering efficacy of plantago psyllium in type II diabetes. Diabetes
Its Complications 1998;12:273–8.
20. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin
sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin
Nutr 1992;56:1061–5.
21. Schwartz SE, Levine RA, Weinstock RS, et al. Sustained pectin
ingestion: effect on gastric emptying and glucose tolerance in non-insulin-dependent diabetic
patients. Am J Clin Nutr 1988;48:1413–7.
22. Hallfrisch J, Scholfield DJ, Behall KM. Diets containing soluble oat
extracts improve glucose and insulin responses of moderately hypercholesterolemic men and
women. Am J Clin Nutr 1995;61:379–84.
23. Doi K, Matsuura M, Kawara A, Baba S. Treatment of diabetes with
glucomannan (konjac mannan). Lancet 1979;1:987–8 [letter].
24. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of
viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome:
results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.
25. Sharma RD, Raghuram TC. Hypoglycaemic effect of fenugreek seeds in
non-insulin dependent diabetic subjects. Nutr Res 1990;10:731–9.
26. Raghuram TC, Sharma RD, Sivakumar B, Sahay BK. Effect of fenugreek
seeds on intravenous glucose disposition in non-insulin dependent diabetic patients.
Phytother Res 1994;8:83–6.
27. Nuttall FW. Dietary fiber in the management of diabetes.
Diabetes 1993;42:503–8.
28. Feskens EJM, Bowles CH, Kromhout D. Inverse association between fish
intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes
Care 1991;14:935–41.
29. Mori TA, Bao DQ, Burke V, et al. Dietary fish as a major component of
a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight
hypertensive subjects. Am J Clin Nutr 1999;70:817–25.
30. Snowdon DA, Phillips RL. Does a vegetarian diet reduce the occurrence
of diabetes? Am J Publ Health 1985;75:507–12.
31. Crane MG, Sample CJ. Regression of diabetic neuropathy with vegan
diet. Am J Clin Nutr 1988;48:926 [abstract #P28].
32. Crane MG, Sample C. Regression of diabetic neuropathy with total
vegetarian (vegan) diet. J Nutr Med 1994;4:431–9.
33. Cohen D, Dodds R, Viberti G. Effect of protein restriction in insulin
dependent diabetics at risk of nephropathy. BMJ 1987;294:795–8.
34. Evanoff G, Thompson C, Bretown J, Weinman E. Prolonged dietary
protein restriction in diabetic nephropathy. Arch Intern Med
1989;149:1129–33.
35. Gin H, Aparicio M, Potauz L, et al. Low-protein, low-phosphorus diet
and tissue insulin sensitivity in insulin-dependent diabetic patients with chronic renal
failure. Nephron 1991;57:411–5.
36. Baba NH, Sawaya S, Torbay N, et al. High protein vs high carbohydrate
hypoenergetic diet for the treatment of obese hyperinsulinemic subjects. Int J Obes Relat
Metab Disord 1999;23:1202–6.
37. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors
determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and
Dutch cohorts of the Seven Countries Study. Diabetes Care 1995;18:1104–12.
38. Feskens EJ, Kromhout D. Habitual dietary intake and glucose tolerance
in euglycaemic men: the Zutphen Study. Int J Epidemiol 1990;19:953–9.
39. Marshall JA, Hoag S, Shetterly S, et al. Dietary fat predicts
conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study.
Diabetes Care 1994;17:50–6.
40. Marshall JA, Hamman RF, Baxter J. High-fat, low-carbohydrate diet and
the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study.
Am J Epidemiol 1991;134:590–603.
41. Uusitupa M, Schwab U, Makimattila S, et al. Effects of two high-fat
diets with different fatty acid compositions on glucose and lipid metabolism in healthy young
women. Am J Clin Nutr 1994;59:1310–6.
42. Sarkkinen E, Schwab U, Niskanen L, et al. The effects of
monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose
metabolism in subjects with impaired glucose tolerance. Eur J Clin Nutr
1996;50:592–8.
43. Garg A, Bananome A, Grundy SM, et al. Comparison of a
high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin
dependent diabetes mellitus. N Engl J Med 1988;319:829–34.
44. Isida K, Mizuno A, Murakami T, Shima K. Obesity is necessary but not
sufficient for the development of diabetes mellitus. Metabolism
1996;45:1288–95.
45. Casassus P, Fontbonne A, Thibult N, et al. Upper-body fat
distribution: a hyperinsulinemia-independent predictor of coronary heart disease mortality.
Arterioscler Thromb 1992;1387–92.
46. Karter AJ, Mayer-Davis EJ, Selby JV, et al. Insulin sensitivity and
abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women.
Diabetes 1996;45:1547–55.
47. Park KS, Hree BD, Lee K-U, et al. Intra-abdominal fat is associated
with decreased insulin sensitivity in healthy young men. Metabolism
1991;40:600–3.
48. Long SD, Swanson MS, O’Brien K, et al. Weight loss in severely
obese subjects prevents the progression of impaired glucose tolerance to type II diabetes.
Diabetes Care 1994;17:372.
49. Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus.
Am J Clin Nutr 1996;63(suppl):426S–9S.
50. Wing RR, Marcuse MD, Blair EH, et al. Caloric restriction per se is a
significant factor in improvements in glycemic control and insulin sensitivity during weight
loss in obese NIDDM patients. Diabetes Care 1994;17:30.
51. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie
diet therapy in obese NIDDM. Diabetes Care 1991;14:802–23.
52. Hersey WC, Graves JE, Pollock ML, et al. Endurance exercise training
improves body composition and plasma insulin responses in 70- to 79-year-old men and women.
Metabol 1994;43:847–54.
53. Rasmussen OW, Lauszus FF, Hermansen K. Effects of postprandial
exercise on glycemic response in IDDM subjects. Diabetes Care 1994;17:1203.
54. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity
and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med
1991;325:147–52.
55. (REF:Bell DSH. Exercise for patients with diabetes—benefits,
risks, precautions. Postgrad Med 1992;92:183–96 [review].
56. Kiechl S, Willeit J, Poewe W, et al. Insulin sensitivity and regular
alcohol consumption: large, prospective, cross sectional population study Bruneck study.
BMJ 1996;313:1040–4.
57. Facchini F, Chen Y-DI, Reaven GM. Light-to-moderate alcohol intake is
associated with enhanced insulin sensitivity. Diabetes Care 1994;17:115.
58. Rimm EB, Chan J, Stampfer MJ, et al. Prospective study of cigarette
smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555–9.
59. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of
moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol
1988;128:549–58.
60. Goden G, Chen X, Desantis R, et al. Effects of ethanol on
carbohydrate metabolism in the elderly. Diabetes 1993;42:28–34.
61. Ben G, Gnudi L, Maran A, et al. Effects of chronic alcohol intake on
carbohydrate and lipid metabolism in subjects with type II (non-insulin-dependent) diabetes.
Am J Med 1991;90:70.
62. Young RJ, McCulloch DK, Prescott RJ, Clarke PF. Alcohol: another risk
factor for diabetic retinopathy? BMJ 1984;288:1035.
63. Connor H, Marks V. Alcohol and diabetes. A position paper prepared by
the Nutrition Subcommittee of the British Diabetic Association’s Medical Advisory
Committee and approved by the Executive Council of the British Diabetic Association. Human
Nutr Appl Nutr 1985;39A:393–9.
64. Ajani UA, Hennekens CH, Spelsberg A, Manson JE. Alcohol consumption
and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med
2000;160:1025–30.
65. Wei M, Gibbons LW, Mitchell TL, et al. Alcohol intake and incidence
of type 2 diabetes in men. Diabetes Care 2000;23:18–22.
66. Valmadrid CT, Klein R, Moss SE, et al. Alcohol intake and the risk of
coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA
1999;282:239–46.
67. Wei M, Gibbons LW, Mitchell TL, et al. Alcohol intake and incidence
of type 2 diabetes in men. Diabetes Care 2000;23:18–22.
68. Stegmayr B, Lithner F. Tobacco and end stage diabetic nephropathy.
BMJ 1987;295:581–2.
69. Scala C, LaPorte RE, Dorman JS, et al. Insulin-dependent diabetes
mellitus mortality—the risk of cigarette smoking.
Circulation1990;82:37–43.
70. Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the
risk of diabetes in women. Am J Public Health 1993;83:211–4.
71. Rindone JP, Austin M, Luchesi J. Effect of home blood glucose
monitoring on the management of patients with non-insulin dependent diabetes mellitus in the
primary care setting. Am J Manag Care 1997;3:1335–8.
72. Faas A, Schellevis FG, Van Eijk JT. The efficacy of self-monitoring
of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care
1997;20:1482–6.
73. [No authors listed.] Position statement: Tests of glycemia in
diabetes. American Diabetes Association. Diabetes Care 2000;23(Suppl
1):S80–2.
74. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in
diabetes. Diabetes Care 1995;18:896–909 [review].
75. Gallichan M. Self monitoring of glucose by people with diabetes:
evidence based practice. BMJ 1997;314:964–7 [review].
76. Steel LG. Identifying technique errors. Self-monitoring of blood
glucose in the home setting. J Gerontol Nurs 1994;20:9–12.
77. Foster SA, Goode JV, Small RE. Home blood glucose monitoring. Ann
Pharmacother 1999;33:355–63 [review].
78. Barringer TA, Kirk JK, Santaniello AC, et al. Effect of a
multivitamin and mineral supplement on infection and quality of life. A randomized,
double-blind, placebo-controlled trial. Ann Intern Med 2003;138:365–71.
79. Herepath WB. Journal Provincial Med Surg Soc 1854:374.
80. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich
yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes
1980;29:919–25.
81. Anderson RA. Chromium in the prevention and control of diabetes.
Diabetes Metab 2000;26:22–7 [review].
82. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate
supplementation attenuates body weight gain and increases insulin sensitivity in subjects with
type 2 diabetes. Diabetes Care 2006;29:1826–32.
83. Anderson RA. Chromium, glucose intolerance and diabetes. J Am
Coll Nutr 1998;17:548–55 [review].
84. Evans GW. The effect of chromium picolinate on insulin controlled
parameters in humans. Int J Biosocial Med Res 1989;11:163–80.
85. Gaby AR, Wright JV. Diabetes. In Nutritional Therapy in Medical
Practice: Reference Manual and Study Guide. Kent, WA: 1996, 54–64 [review].
86. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental-chromium
effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming
controlled low-chromium diets. Am J Clin Nutr 1991;54:909–16.
87. Jovanovic L, Gutierrez M, Peterson CM. Chromium supplementation for
women with gestational diabetes. J Trace Elem Exptl Med 1999;12:91–8.
88. Anderson RA, Polansky MM, Bryden NA, et al. Chromium supplementation
of human subjects: effects on glucose, insulin, and lipid variables. Metabolism
1983;32:894–9.
89. Urberg M, Zemel MB. Evidence for synergism between chromium and
nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism
1987;36:896–9.
90. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on
serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449–52.
91. Hermann J, Chung H, Arquitt A, et al. Effects of chromium or copper
supplementation on plasma lipids, plasma glucose and serum insulin in adults over age fifty.
J Nutr Elderly 1998;18:27–45.
92. Sherman L, Glennon JA, Brech WJ, et al. Failure of trivalent chromium
to improve hyperglycemia in diabetes mellitus. Metabolism 1968;17:439–42.
93. Rabinowitz MB, Gonick HC, Levin SR, Davidson MB. Effects of chromium
and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes
Care 1983;6:319–27.
94. Uusitupa MI, Kumpulainen JT, Voutilainen E, et al. Effect of
inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in
noninsulin-dependent diabetics. Am J Clin Nutr 1983;38:404–10.
95. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of
supplemental chromium improve glucose and insulin variables in individuals with type 2
diabetes. Diabetes 1997;46:1786–91.
96. Gaby AR, Wright JV. Nutritional protocols: diabetes mellitus. In
Nutritional Therapy in Medical Practice: Protocols and Supporting Information. Kent, WA:
1996, 10.
97. Paolisso G, Scheen A, D’Onofrio FD, Lefebvre P. Magnesium and
glucose homeostasis. Diabetologia 1990;33:511–4 [review].
98. Eibl NL, Schnack CJ, Kopp H-P, et al. Hypomagnesemia in type II
diabetes: effect of a 3-month replacement therapy. Diabetes Care 1995;18:188.
99. Paolisso G, Sgambato S, Pizza G, et al. Improved insulin response and
action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care
1989;12:265–9.
100. Lima M, Cruz T, Carreiro Pousada J, et al: The effect of magnesium
supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care
1998;21:682–6.
101. Paolisso G, Sgambato S, Gambardella A, et al. Daily magnesium
supplements improve glucose handling in elderly subjects. Am J Clin Nutr
1992;55:1161–7.
102. Smellie WS, O’Reilly DS, Martin BJ, Santamaria J. Magnesium
replacement and glucose tolerance in elderly subjects. Am J Clin Nutr
1993;57:594–6 [letter].
103. de Valk HW, Verkaaik R, van Rijn HJM, et al. Oral magnesium
supplementation in insulin-requiring type 2 diabetic patients. Diabet Med
1998;15:503–7.
104. American Diabetes Association. Magnesium supplementation in the
treatment of diabetes. Diabetes Care 1992;15:1065–7.
105. McNair P, Christiansen C, Madsbad S, et al. Hypomagnesemia, a risk
factor in diabetic retinopathy. Diabetes 1978;27:1075–7.
106. Mimouni F, Miodovnik M, Tsang RC, et al. Decreased maternal serum
magnesium concentration and adverse fetal outcome in insulin-dependent diabetic women.
Obstet Gynecol 1987;70:85–9.
107. American Diabetes Association. Magnesium supplementation in the
treatment of diabetes. Diabetes Care 1992;15:1065–7.
108. Konrad T, Vicini P, Kusterer K, et al. alpha lipoic acid treatment
decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean
and obese patients with type 2 diabetes. Diabetes Care 1999;22:280–7.
109. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral
treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic
polyneuropathy. Diabet Med 1999;16:1040–3.
110. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral
treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic
polyneuropathy. Diabet Med 1999;16:1040–3.
111. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic
polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter
randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic
Neuropathy. Free Radic Res 1999;31:171–9.
112. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the
antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month
randomized controlled multicenter trial (DEKAN Study). Diabetes Care
1997;20:369–73.
113. Jacob S, Ruus P, Hermann R, et al. Oral administration of
RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus:
a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309–14.
114. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic
diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter
randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in
Diabetic Neuropathy. Diabetes Care 1999;22:1296–301.
115. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with
alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Diabetes Care 2006;29:2365–70.
116. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid
on the progression of endothelial cell damage and albuminuria in patients with diabetes
mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–83.
117. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human
diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med
1990;7:319–23.
118. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids.
Eur J Clin Nutr 1995;49(Suppl. 3):S190–7 [review].
119. Melga P, Giusto M, Ciuchi E, et al. Dietary fiber in the dietetic
therapy of diabetes mellitus. Experimental data with purified glucomannans. Riv Eur Sci
Med Farmacol 1992;14:367–73 [in Italian].
120. Huang CY, Zhang MY, Peng SS, et al. Effect of Konjac food on blood
glucose level in patients with diabetes. Biomed Environ Sci 1990;3:123–31.
121. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan
(glucomannan) improves glycemia and other associated risk factors for coronary heart disease
in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care
1999;22:913–9.
122. Vorster HH, Lotter AP, Odendaal I, et al. Benefits from
supplementation of the current recommended diabetic diet with gel fibre. Int Clin Nutr
Rev 1988;8:140–6.
123. Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the
treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. Minerva
Ginecol 1990;42:271–4 [in Italian].
124. Knekt P, Reunanen A, Marniumi J, et al. Low vitamin E status is a
potential risk factor for insulin-dependent diabetes mellitus. J Intern Med
1999;245:99–102.
125. Salonen JT, Nyssonen K, Tuomainen T-P, et al. Increased risk of
non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year
follow up study in men. BMJ 1995;311:1124–7.
126. Bierenbaum ML, Noonan FJ, Machlin LJ, et al. The effect of
supplemental vitamin E on serum parameters in diabetics, post coronary and normal subjects.
Nutr Rep Int 1985;31:1171–80.
127. Paolisso G, D’Amore A, Giugliano D, et al. Pharmacologic doses
of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic
patients. Am J Clin Nutr 1993;57:650–6.
128. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E
supplements improve metabolic control but not insulin secretion in elderly type II diabetic
patients. Diabetes Care 1993;16:1433–7.
129. Tütüncü NB, Bayraktar M, Varli K. Reversal of
defective nerve condition with vitamin E supplementation in type 2 diabetes. Diabetes
Care 1998;21:1915–8.
130. Paolisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of
vitamin E and insulin action in elderly subjects. Am J Clin Nutr
1994;59:1291–6.
131. Paolisso G, Gambardella A, Galzerano D, et al. Antioxidants in
adipose tissue and risk of myocardial infarction. Lancet 1994;343:596 [letter].
132. Tütüncü NB, Bayraktar M, Varli K. Reversal of
defective nerve condition with vitamin E supplementation in type 2 diabetes. Diabetes
Care 1998;21:1915–8.
133. Ross WM, Creighton MO, Stewart-DeHaan PJ, et al. Modelling cortical
cataractogenesis: 3. In vivo effects of vitamin E on cataractogenesis in diabetic rats.
Can J Ophthalmol 1982;17:61.
134. Bursell SE, Schlossman DK, Clermont AC, et al. High-dose vitamin E
supplementation normalizes retinal blood flow and creatinine clearance in patients with type I
diabetes. Diabetes Care 1999;22:1245–51.
135. Ceriello A, Giugliano D, Quatraro A, et al. Vitamin E reduction of
protein glycosylation in diabetes. Diabetes Care 1991;14:68–72.
136. Duntas L, Kemmer TP, Vorberg B, Scherbaum W. Administration of
d-alpha-tocopherol in patients with insulin-dependent diabetes mellitus. Curr Ther
Res 1996;57:682–90.
137. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E
supplements improve metabolic control but not insulin secretion in elderly type II diabetic
patients. Diabetes Care 1993;16:1433–7.
138. Jain SK, McVie R, Jaramillo JJ, et al. Effect of modest vitamin E
supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in
type I diabetic patients. J Am Coll Nutr 1996;15:458–61.
139. Jain SK, McVie R, Smith T. Vitamin E supplementation restores
glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic
children. Diabetes Care 2000;23:1389–94.
140. Reaven PD, Barnett J, Herold DA, Edelman S. Effect of vitamin E on
susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to
oxidation and on protein glycation in NIDDM. Diabetes Care 1995;18:807.
141. Bursell S-E, Schlossman DK, Clermont AC, et al. High-dose vitamin E
supplementation normalizes retinal blood flow and creatineine clearance in patients with type
I diabetes. Diabetes Care 1999;22:1245–51.
142. Fuller CJ, Chandalia M, Garg A, et al. RRR-alpha-tocopheryl acetate
supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative
susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin
Nutr 1996;63:753–9.
143. Skrha J, Sindelka G, Kvasnicka J, Hilgertova J. Insulin action and
fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus. Diabetes Res Clin
Pract 1999;44:27–33.
144. Leppälä JM, Virtamo J, Fogelholm R, et al. Vitamin E and
beta carotene supplementation in high risk for stroke: A subgroup analysis of the
alpha-tocopherol, beta-carotene cancer prevention study. Arch Neurol
2000;57:1503–9.
145. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation
of proteins. Diabetes 1992;41:167–73.
146. Will JC, Tyers T. Does diabetes mellitus increase the requirement
for vitamin C? Nutr Rev 1996;54:193–202 [review].
147. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation
in diabetes mellitus. Ann Nutr Metab 1995;39:217–23.
148. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving
from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll
Nutr 1995;14:387–92.
149. Will JC, Tyers T. Does diabetes mellitus increase the requirement
for vitamin C? Nutr Rev 1996;54:193–202 [review].
150. McAuliffe AV, Brooks BA, Fisher EJ, et al. Administration of
ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary
albumin excretion. Nephron 1998;80:277–84.
151. Branch DR. High-dose vitamin C supplementation increases plasma
glucose. Diabetes Care 1999;22:1218 [letter].
152. Mayer-Davis E, Bell RA, Reboussin BA, et al. Antioxidant nutrient
intake and diabetic retinopathy. The San Luis Valley Diabetes Study. Ophthalmology
1998;105:2264–70.
153. Wilson RG, Davis RE. Serum pyridoxal concentrations in children with
diabetes mellitus. Pathology 1977;9:95–9.
154. Davis RE, Calder JS, Curnow DH. Serum pyridoxal and folate
concentrations in diabetics. Pathology 1976;8:151–6.
155. McCann VJ, Davis RE. Serum pyridoxal concentrations in patients with
diabetic neuropathy. Aust N Z J Med 1978;8:259–61.
156. Spellacy WN, Buhi WC, Birk SA. Vitamin B6 treatment of gestational
diabetes mellitus. Am J Obstet Gynecol 1977;127:599–602.
157. Coelingh HJT, Schreurs WHP. Improvement of oral glucose tolerance in
gestational diabetes by pyridoxine. BMJ 1975;3:13–5.
158. Spellacy WN, Buhi WC, Birk SA. The effects of vitamin B6 on
carbohydrate metabolism in women taking steroid contraceptives: preliminary report.
Contraception 1972;6:265–73.
159. Passariello N, Fici F, Giugliano D, et al. Effects of pyridoxine
alpha-ketoglutarate on blood glucose and lactate in type I and II diabetics. Int J Clin
Pharmacol Ther Toxicol 1983;21:252–6.
160. Solomon LR, Cohen K. Erythrocyte O2 transport and metabolism and
effects of vitamin B6 therapy in type II diabetes mellitus. Diabetes
1989;38:881–6.
161. Rao RH, Vigg BL, Rao KSJ. Failure of pyridoxine to improve glucose
tolerance in diabetics. J Clin Endocrinol Metab 1980;50:198–200.
162. Abbas ZG, Swai ABM. Evaluation of the efficacy of thiamine and
pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East African
Med J 1997;74:804–8.
163. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B
combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes
1996;104:311–6.
164. Coggeshall JC, Heggers JP, Robson MC, Baker H. Biotin status and
plasma glucose in diabetics. Ann NY Acad Sci 1985;447:389–92.
165. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic
peripheral neuropathy. Biomed Pharmacother 1990;44:511–4.
166. Yamane K, Usui T, Yamamoto T, et al. Clinical efficacy of
intravenous plus oral mecobalamin in patients with peripheral neuropathy using vibration
perception thresholds as an indicator of improvement. Curr Ther Res
1995;56:656–70 [review].
167. Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin
treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern
Med 1999;38:472–5.
168. Molnar GD, Berge KG, Rosevear JW, et al. The effect of nicotinic
acid in diabetes mellitus. Metabolism 1964;13:181–9.
169. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance,
plasma insulin, and uric acid excretion in man during chronic administration in nicotinic
acid. Metabolism 1971;20:1031–5.
170. Clearly JP. The importance of oxidant injury as a cause of impaired
mitochondrial oxidation in diabetes. J Orthomolec Med 1988;3:164–74.
171. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of
3-hydroxy-3-methylglutaryl coenzyme I reductase inhibitors on serum coenzyme Q10 in diabetic
patients. Arzneimittelforschung 1999;49:324–9.
172. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood
sugar and ketone bodies of diabetics. J Vitaminol (Kyoto) 1966;12:293–8.
173. Abdel-Aziz MT, Abdou MS, Soliman K, et al. Effect of carnitine on
blood lipid pattern in diabetic patients. Nutr Rep Int 1984;29:1071–9.
174. Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves
pain, nerve regeneration, and vibratory perception in patients with chronic diabetic
neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care
2005;28:89–94.
175. Nakamura T, Higashi A, Nishiyama S, et al. Kinetics of zinc status
in children with IDDM. Diabetes Care 1991;14:553–7.
176. Niewoehner CB, Allen JI, Boosalis M, et al. Role of zinc
supplementation in type II diabetes mellitus. Am J Med 1986;81:63–8.
177. Crary EJ, McCarty MF. Potential clinical applications for high-dose
nutritional antioxidants. Med Hypotheses 1984;13:77–98.
178. Labriji-Mestaghanmi H, Billaudel B, Garnier PE, Sutter BCJ. Vitamin
D and pancreatic islet function. I. Time course for changes in insulin secretion and content
during vitamin deprivation and repletion. J Endocrine Invest
1988;11:577–84.
179. Boucher BJ. Inadequate vitamin D status: does it contribute to the
disorders comprising syndrome ‘X’? Br J Nutr 1998;79:315–27
[review].
180. Borissova AM, Tankova T, Kirilov G, et al. The effect of vitamin D3
on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J
Clin Pract 2003;57:258–61.
181. Lee P, Chen R. Vitamin D as an analgesic for patients with type 2
diabetes and neuropathic pain. Arch Intern Med 2008;168:771–2.
182. Salway JG, Whitehead L, Finnegan JA, et al. Effect of
myo-inositol on peripheral-nerve function in diabetes. Lancet
1978;2:1282–4.
183. Franconi F, Di Leo MA, Bennardini F, Ghirlanda G. Is taurine
beneficial in reducing risk factors for diabetes mellitus? Neurochem Res
2004;29:143–50 [review].
184. Brons C, Spohr C, Storgaard H, et al. Effect of taurine treatment on
insulin secretion and action, and on serum lipid levels in overweight men with a genetic
predisposition for type II diabetes mellitus. Eur J Clin Nutr 2004;58:1239-47.
185. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of taurine and
vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen
concentrations in patients with diabetic nephropathy. Nephron
1999;83:361–2.
186. Zak A, Zeman M, Hrabak P, et al. Changes in the glucose tolerance
and insulin secretion in hypertriglyceridemia: effects of dietary n-3 fatty acids. Nutr
Rep Int 1989;39:235–42.
187. Popp-Snijders C, Schouten JA, Heine RJ, et al. Dietary
supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in
non-insulin-dependent diabetes. Diabetes Res 1987;4:141–7.
188. Albrink MJ, Ullrich IH, Blehschmidt NG, et al. The beneficial effect
of fish oil supplements on serum lipids and clotting function of patients with type II
diabetes mellitus. Diabetes 1986;35 (suppl 1):43A [abstract #172].
189. Wei I, Ulchaker M, Sheehan J. Effect of omega-3 fatty acids (FA) in
non-obese non-insulin dependent diabetes (NIDDM). Am Clin Nutr 1988;47:775 [abstract
#70].
190. Okuda Y, Mizutani M, Ogawa M, et al. Long-term effects of
eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type
II diabetes mellitus. J Diabetes Complications 1996;10:280–7.
191. Vandongen R, Mori TA, Codde JP, et al. Hypercholesterolaemic effect
of fish oil in insulin-dependent diabetic patients. Med J Aust
1988;148:141–3.
192. Schectman G, Kaul S, Kissebah AH. Effect of fish oil concentrate on
lipoprotein composition in NIDDM. Diabetes 1988;37:1567–73.
193. Stackpoole PW, Alig J, Kilgore LL, et al. Lipodystrophic diabetes
mellitus. Investigations of lipoprotein metabolism and the effects of omega-3 fatty acid
administration in two patients. Metabolism 1988;37:944–51.
194. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect
of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med
1988;108:663–8.
195. Gaby A. Preventing complications of diabetes Townsend
Letter 1985;32:307 [editorial].
196. Halberstam M, Cohen N, Schlimovich P, et al. Oral vanadyl sulfate
improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes
1996;45:659–66.
197. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on
carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus.
Metabolism 1996;45:1130–5.
198. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl
sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
Metabolism 2000;49:400–10.
199. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl
sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies.
Metabolism 2000;49:400–10.
200. Yamashita K, Kawai K, Itakura M. Effect of fructo-oligosaccharides
on blood glucose and serum lipids in diabetic subjects. Nutr Res
1984;4:961–6.
201. Roberfroid M. Dietary fibre, inulin and oligofructose. A review
comparing their physiological effects. Crit Rev Food Sci Nutr 1993;33:103–48
[review].
202. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel. Effect of
nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and
glucose absorption in young healthy male subjects. Eur J Clin Nutr
1999;53:1–7.
203. Luo J, Rizkalla SW, Alamowitch C, et al. Chronic consumption of
short-chain fructooligosaccharides by health subjects decreased basal hepatic glucose
production but had no effect on insulin-stimulated glucose metabolism. Am J Clin Nutr
1996;63:939–45.
204. Kosenko LG. Concentration of trace elements in the blood of patients
with diabetes mellitus. Fed Proc Transl (Suppl) 1965;24:237–8.
205. Baly DL, Schneiderman JS, Garcia-Welsh AL. Effect of manganese
deficiency on insulin binding, glucose transport and metabolism in rat adipocytes. J
Nutr 1990;120:1075–9.
206. Rubenstein AH, Levin NW, Elliott GA. Hypoglycaemia induced by
manganese. Nature (London) 1962;194:188–9.
207. Eckel RH, Hanson AS, Chen AY, et al. Dietary substitution of
medium-chain triglycerides improves insulin-mediated glucose metabolism in non-insulin
dependent diabetics. Diabetes 1992;41:641–7.
208. Trudy J, Yost RN, Erskine JM, et al. Dietary substitution of
medium-chain triglycerides in subjects with non-insulin dependent diabetes mellitus in an
ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism. J
Am Coll Nutr 1994;13:615–22.
209. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified
amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. Mayo
Clin Proc 1987;62:249–55.
210. Boivin M, Flourie B, Rizza RA, et al. Gastrointestinal and metabolic
effects of amylase inhibition in diabetics. Gastroenterology
1988;94:387–94.
211. Lankisch M, Layer P, Rizza RA, DiMagno EP. Acute postprandial
gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese, and
diabetic humans. Pancreas 1998;17:176–81.
212. Holt PR, Thea D, Yang MY, Kotler DP. Intestinal and metabolic
responses to an alpha-glucosidase inhibitor in normal volunteers. Metabolism
1988;37:1163–70.
213. Layer P, Rizza RA, Zinsmeister AR, et al. Effect of a purified
amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes
mellitus. Mayo Clin Proc 1986;61:442–7.
214. Rajasekaran S, Sivagnanam K, Subramanian S. Hypoglycemic effect of
Aloe vera gel on streptozotocin-induced diabetes in experimental rats. J Med Food
2004;7:61–6.
215. Yongchaiyudha S, Rungpitarangs V, Bunyapraphatsara N,
Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial
in new cases of diabetes mellitus. Phytomedicine 1996;3:241–3.
216. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V,
Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. II. Clinical trial
in diabetes mellitus patients in combination with glibenclamide. Phytomedicine
1996;3:245–8.
217. Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical
effectiveness. Br J Gen Pract 1999;49:823–8 [review].
218. [No authors listed.] Treatment of painful diabetic neuropathy with
topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study
Group. Arch Intern Med 1991;151:2225–9.
219. [No authors listed.] Effect of treatment with capsaicin on daily
activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes
Care 1992;15:159–65.
220. Hannan JM, Rokeya B, Faruque O, et al. Effect of soluble dietary
fibre fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet
aggregation status of Type 2 diabetic model rats. J Ethnopharmacol
2003;88:73–7.
221. Broca C, Manteghetti M, Gross R, et al. 4-Hydroxyisoleucine: effects
of synthetic and natural analogues on insulin secretion. Eur J Pharmacol
2000;390:339–45.
222. Puri D, Prabhu KM, Murthy PS. Mechanism of action of a hypoglycemic
principle isolated from fenugreek seeds. Indian J Physiol Pharmacol
2002;46:457–62.
223. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of
fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr 1988;42:51–4.
224. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Trigonella
foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with
coronary artery disease. Prostaglandins Leukot Essent Fatty Acids
1997;56:379–84.
225. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum
(fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a
double blind placebo controlled study. J Assoc Physicians India
2001;49:1057–61.
226. Anderson JW, Allgood LD, Turner J, et al. Effects of psyllium on
glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. Am
J Clin Nutr 1999;70:466–73.
227. Zhang T, Hoshino M, Iguchi K, et al. Ginseng root: Evidence for
numerous regulatory peptides and insulinotropic activity. Biomed Res
1990;11:49–54.
228. Suzuki Y, Hikino H. Mechanisms of hypoglycemic activity of panaxans
A and B, glycans of Panax ginseng roots: Effects on plasma levels, secretion,
sensitivity and binding of insulin in mice. Phytother Res 1989;3:20–4.
229. Waki I, Kyo H, Yasuda M, Kimura M. Effects of a hypoglycemic
component of ginseng radix on insulin biosynthesis in normal and diabetic animals. J Pharm
Dyn 1982;5:547–54.125.
230. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in
non-insulin-dependent diabetic patients. Diabetes Care 1995;18:1373–5.
231. Vuksan V, Sivenpiper JL, Koo VY, et al. American ginseng (Panax
quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with
type 2 diabetes mellitus. Arch Intern Med 2000;160:1009–13.
232. Vuksan V, Sivenpiper JL, Koo VYY, et al. American ginseng (Panax
quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with
type 2 diabetes mellitus. Arch Intern Med 2000;160:1009–13.
233. Viseshakul D, Premvatana P, Chularojmontri V, et al. Improved
glucose tolerance induced by long term dietary supplementation with hairy basal seeds
(Ocimum canum Sim) in diabetics. J Med Assoc Thailand
1985;68:408–11.
234. Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single
blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus.
Int J Clin Pharmacol Ther 1996;34:406–9.
235. Rai V, Mani UV, Iyer UM. Effect of Ocimum sanctum leaf
powder on blood lipoproteins, glycated protein and total amino acids in patients with
non-insulin-dependent diabetes mellitus. J Nutr Environ Med 1997;7:113–8.
236. Rai V, Mani UV. Effect of ocimum sanctum leaf powder on blood
lipoproteins. J Nutr Environ Med 1997;7:113–18.
237. Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single
blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus.
Int J Clin Pharmacol Ther 1996;34:406–9.
238. Baskaran K, Ahmath BK, Shanmugasundaram KR, Shanmugasundaram ERB.
Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent
diabetes mellitus patients. J Ethnopharmacol 1990;30:295–305.
239. Shanmugasundaram ERB, Rajeswari G, Baskaran K, et al. Use of
Gymnema sylvestre leaf extract in the control of blood glucose insulin-dependent diabetes
mellitus. J Ethnopharmacol 1990;30:281–94.
240. Joffe DJ, Freed SH. Effect of extended release gymnema sylvestre
leaf extract (Beta Fast GXR) alone or in combination with oral hypoglycemics or insulin
regimens for type 1 and type 2 diabetes. Diabetes In ControlNewsletter
2001;76:no page number.
241. Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum
marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized,
double-blind, placebo-controlled, clinical trial. Phytother Res
2006;20:1036–9.
242. Hussain SA. Silymarin as an adjunct to glibenclamide therapy
improves long-term and postprandial glycemic control and body mass index in type 2 diabetes.
J Med Food 2007;10:543–7.
243. Leatherdale BA, Panesar RK, Singh G, et al. Improvement of glucose
tolerance due to Momordica charantia (karela). BMJ
1981;282:1823–4.
244. Srivastava Y, Venkatakrishna-bhatt H, Verma Y, et al. Antidiabetic
and adaptogenic properties of Momordica charantia extract: An experimental and
clinical evaluation. Phytother Res 1993;7:285–9.
245. Welihinda J, Karunanaya E, Sheriff MHB, Jayasinghe K. Effect of
Momordica charantia on the glucose tolerance in maturity onset diabetes. J
Ethnopharmacol 1986;17:277–82.
246. Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves glucose and
lipids of people with type 2 diabetes. Diabetes Care 2003;26:3215–8.
247. Vanschoonbeek K, Thomassen BJ, Senden JM, et al. Cinnamon
supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients.
J Nutr 2006;136:977–80.
248. Blevins SM, Leyva MJ, Brown J, et al. Effect of cinnamon on glucose
and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care
2007;30:2236–7.
249. Judy WV, Hari SP, Stogsdill WW, et al. Antidiabetic activity of a
standardized extract (Glucosol) from Lagerstroemia speciosa leaves in Type II
diabetics. A dose-dependence study. J Ethnopharmacol 2003;87:115–7.
250. Jain RC, Sachdev KN. A note on hypoglycemic action of onion in
diabetes. Curr Med Pract 1971;15:901–2.
251. Mathew PT, Augusti KT. Hypoglycaemic effect of onion, Allium
cepa Linn, on diabetes mellitus, a preliminary report. Ind J Physiol Pharmacol
1975;19:231–7.
252. Tjokroprawiro A, Pikir BS, Budhiarta AA, et al. Metabolic effects of
onion and green beans on diabetic patients. Tohoku J Exp Med
1983;141(suppl):671–6.
253. Sharma KK, Gupta RK, Gupta S, Samuel KC. Antihyperglycemic effect of
onion: Effect on fasting blood sugar and induced hyperglycemia in man. Ind J Med Res
1977;65:422–9.
254. Scharrer A, Ober M. Anthocyanoside in der Behandlung von
Retinopathien. Klin Monatsblatt Augenheilk 1981;178:386–9.
255. Maxwell SR, et al. Poor glycaemic control is associated with reduced
serum free radical scavenging (antioxidant) activity in non-insulin-dependent diabetes
mellitus. Ann Clin Biochem 1997;34( Pt 6):638–44.
256. Jayaprakasam B, Vareed SK, Olson LK, Nair MG. Insulin secretion by
anthocyanins and anthocyanidins. J Agric Food Chem 2005;53:28–31.
257. Koltringer P, Langsteger W, Lind P, et al. [Ginkgo biloba extract
and folic acid in the therapy of changes caused by autonomic neuropathy]. Acta Med
Austriaca 1989;16:35–7 [in German].
258. Alam MM, Siddiqui MB, Hussain W. Treatment of diabetes through
herbal drugs in rural India. Fitoterapia 1990;61:240–2.
259. Sachdewa A, Khemani LD. Effect of Hibiscus rosa sinensis
Linn ethanol flower extract on blood glucose and lipid profile in streptozotocin induced
diabetes in rats. J Ethnopharmacol 2003;89:61–6.
260. Gray AM, Flatt PR. Insulin-secreting activity of the traditional
antidiabetic plant Viscum album (mistletoe). J Endocrinol
1999;160:409–14.
261. Swanson-Flatt SK, Day C, Bailey CJ, Flatt PR. Evaluation of
traditional plant treatments for diabetes: Studies in streptozotocin-diabetic mice. Acta
Diabetologica Latina 1989;26:51–5.
262. Peirce A. Practical Guide to Natural Medicines. New York:
William Morrow and Co., 1999, 469–71.
263. Van der Hem LG, van der Vliet JA, Bocken CF, et al. Ling Zhi-8:
studies of a new immunomodulating agent. Transplantation 1995;60:438–43.
264. Jones K. Reishi mushroom: Ancient medicine in modern times. Alt
Compl Ther 1998;4:256–66 [review].
265. Feng M, Li Y, Pang B, et al. Acupuncture combined with application
of xiaoke plaster for treatment of 309 cases of diabetes mellitus. J Tradit Chin Med
1997;17:247–9.
266. Chen JF. A hemorrheological study on the effect of acupuncture in
treating diabetes mellitus. J Tradit Chin Med 1987;7:95–100.
267. Chen D, Gong D, Zhai Y. Clinical and experimental studies in
treating diabetes mellitus by acupuncture. J Tradit Chin Med 1994;14:163–6.
268. Chen JF, Wei J. Changes of plasma insulin level in diabetics treated
with acupuncture. J Tradit Chin Med 1985;5:79–84.
269. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment
of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin
Pract 1998;39:115–21.
270. Zheg HT, Huang XM, Sun JH. Treatment of diabetic cystopathy by
acupuncture and moxibustion. J Tradit Chin Med 1986;6:243–8.
271. Zhang W. Acupuncture for treatment of diabetic urinary bladder
neural dysfunction—a report of 36 cases. J Tradit Chin Med
1997;17:211–3.